| [1] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023 [J]. CA Cancer J Clin, 2023, 73(1):17-48.
|
| [2] |
郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3): 212-220.
|
| [3] |
Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer[J]. N Engl J Med, 2001, 345(23): 1655-1659.
|
| [4] |
Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon Alfa alone in metastatic renal-cell carcinoma: a randomised trial[J]. Lancet, 2001, 358(9286): 966-970.
|
| [5] |
Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma[J]. N Engl J Med, 2018, 379(5): 417-427.
|
| [6] |
Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma[J]. Eur Urol, 2019, 75(1): 111-128.
|
| [7] |
Psutka SP, Chang SL, Cahn D, et al. Reassessing the role of cytoreductive nephrectomy for metastatic renal cell carcinoma in 2019[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 276-283.
|
| [8] |
Larcher A, Fallara G, Rosiello G, et al. Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines[J]. Eur Urol, 2020, 78(3): 321-326.
|
| [9] |
Figlin RA. Renal cell carcinoma: management of advanced disease[J]. J Urol, 1999, 161(2): 381-386.
|
| [10] |
Janiszewska AD, Poletajew S, Wasiutyński A. Spontaneous regression of renal cell carcinoma[J]. Contemp Oncol, 2013, 17(2): 123-127.
|
| [11] |
Milowsky MI, Nanus DM. Advanced renal cell carcinoma[J]. Curr Treat Options Oncol, 2001, 2(5): 437-445.
|
| [12] |
Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis[J]. J Urol, 2004, 171(3): 1071-1076.
|
| [13] |
Zini L, Capitanio U, Perrotte P, et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma[J]. Urology, 2009, 73(2): 342-346.
|
| [14] |
Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy[J]. J Urol, 2007, 177(6): 1978-1984.
|
| [15] |
Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium[J]. Eur Urol, 2014, 66(4): 704-710.
|
| [16] |
Hanna N, Sun M, Meyer CP, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study[J]. J Clin Oncol, 2016, 34(27): 3267-3275.
|
| [17] |
Petrelli F, Coinu A, Vavassori I, et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis[J]. Clin Genitourin Cancer, 2016, 14(6): 465-472.
|
| [18] |
Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy[J]. J Urol, 2011, 185(1): 60-66.
|
| [19] |
Motzer RJ, Russo P. Cytoreductive nephrectomy - patient selection is key[J]. N Engl J Med, 2018, 379(5): 481-482.
|
| [20] |
Pierorazio PM, McKiernan JM, McCann TR, et al. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed[J]. BJU Int, 2007, 100(4): 755-759.
|
| [21] |
Barbastefano J, Garcia JA, Elson P, et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy[J]. BJU Int, 2010, 106(9): 1266-1269.
|
| [22] |
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19): 1803-1813.
|
| [23] |
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med, 2018, 378(14): 1277-1290.
|
| [24] |
Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1116-1127.
|
| [25] |
Motzer R J, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1103-1115.
|
| [26] |
Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database[J]. Urol Oncol, 2020, 38(6): 604.e9-604.e17.
|
| [27] |
Bakouny Z, El Zarif T, Dudani S, et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium[J]. Eur Urol, 2023, 83(2): 145-151.
|
| [28] |
Chen B, Li J, Huang Y, et al. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis[J]. Int J Surg, 2023, 109(4): 982-994.
|
| [29] |
Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma[J]. J Urol, 1997, 158(5): 1691-1695.
|
| [30] |
McIntosh AG, Umbreit EC, Holland LC, et al. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy[J]. Cancer, 2020, 126(17): 3950-3960.
|
| [31] |
Takemura K, Ernst MS, Navani V, et al. Characterization of patients with metastatic renal cell carcinoma undergoing deferred, upfront, or no cytoreductive nephrectomy in the era of combination immunotherapy: results from the international metastatic renal cell carcinoma database consortium[J]. Eur Urol Oncol, 2023: S2588-9311(23)00217-1.
|
| [32] |
Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial[J]. JAMA Oncol, 2019, 5(2): 164-170.
|
| [33] |
Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition[J]. N Engl J Med, 2017, 377(25): 2500-2501.
|
| [34] |
MacFarlane AW 4th, Jillab M, Plimack ER, et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection[J]. Cancer Immunol Res, 2014, 2(4): 320-331.
|
| [35] |
Justine P, Ava S, Kevin H, et al. Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC)[J]. J Clin Oncol, 2022, 40(6): 334.
|
| [36] |
Bhindi B, Habermann EB, Mason RJ, et al. Comparative survival following initial cytoreductive nephrectomy versus initial targeted therapy for metastatic renal cell carcinoma[J]. J Urol, 2018, 200(3): 528-534.
|